Sangamo Biosciences (NASDAQ:SGMO) traded in a range yesterday that spanned from a low of $6.05 to a high of $6.80. Yesterday, the shares gained 47.7%, which took the trading range above the 3-day high of $4.64 on volume of 10.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
The Sangamo Therapeutics’s Return on Assets were -40.90%%. At the close of the day, the stock reported a Market Cap of $491.54M in the Biotechnology Industry.
The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions. Longer term, the trend strength is in the Top 1%. Long term indicators fully support a continuation of the trend.
The company traded a total volume of 15,643,100, and the stock saw a change of 60.92% in the previous trading session. The company reported a 52-Week High of $-7.89% and a52-Week Low of $164.15%. The monthly Volatility of Sangamo Therapeutics, Inc. stood at 7.09%.
Sangamo Therapeutics, Inc. announced EPS of $-1.02. This represents a growth of -74.10% in EPS this year compared to what was reported last financial year and represents an overall growth of -7.50% over the past five year. The company is now projecting an EPS growth of -% in the next five years.
Sangamo Therapeutics, Inc.’s ownership was spread out with Insider Ownership amounting to 0.10% while Institutional Ownership amounted to 58.90%. Total insider transactions was 0.00% and total Institutional Transactions was 0.48%.
Return on Assets reported was -40.90%. Return on Equity for the financial year was -46.30% while Return on Investments was -51.80%. The company closed the year with a Total Debt/Equity of 0.03 out of which Long Term Debt/Equity was 0.03. Current and quick ratio amounted to 11.30 and 11.30 respectively.
The company has 70.22M shares outstanding at a price of $7.00 per share.
EPS growth reported for this year was -74.10%. For the past five years, the company has reported EPS growth of -7.50% with EPS growth for the next year projected to be -8.00%.